Novel Therapeutics and Drug Targets 1

• 431 · PDF A new approach methodology (NAM) for specificity testing: ISTAND qualification of the membrane proteome array to evaluate off-target binding of MAb-based therapies Diana Norden, Jonathan T. Sullivan, Carmen Navia, Jonathan Richards, Alexander Hobby, Rachel Fong, Benjamin Doranz
• 432 · PDF Targeting Brachyury with small molecules: A new therapeutic paradigm for chordoma and neuroendocrine carcinomas Gaelle Mercenne, Brian McEllin, Julia Robbins, Lindsay Pino, Gavin Hirst, Alexander Joel Federation
• 433 · PDF A robust automated workflow for precise oncoprotein quantification to accelerate targeted degradation and oncology research Alex M. Strom, Quynh Nguyen, Qiuyan Ma
• 434 · PDF Target agnostic phage display for nanobodies that alter immune cell function Peter Qian Leung, Todd A. Aguilera, Eslam A. Elghonaimy, Thillai Sekar, Mike Whitney, Isaac Gonzalez
• 435 · PDF Novel anti-CD3 heavy chain-only antibodies for use in T-cell engaging therapeutics Noel Pauli, Hannah Watkins, Paul Khalife, Elizabeth Parker, Cameron Henkel, Todd Boland, Hailey Heston, Christin Strong, Jinfu Zhao, Irina Burnina, Michael Brown, Jessica Dawson, Garrett Rappazzo, Beth Sharkey, Morgan Morrill, Michael Battles, Robert Pejchal, Eric Krauland
• 436 · PDF Redox-DNA repair co-targeting with IP-DNQ and rucaparib induces oxidative DNA damage and GSDME-mediated pyroptosis in NQO1-positive tumors Soumya Tumbath, Hao Zhou, Jiangwei Wang, Lingxiang Jiang, Elin H. Chen, Celine Thormann, Xiumei Huang
• 437 · PDF Targeting RNA demethylase ALKBH5 with mefloquine enhances antitumor immunity and reduces osteosarcoma progression and metastasis Victoria Chen Mai, Daisy Medina, Manjeet K. Rao
• 438 · PDF The multibody drug conjugate (MDC) BD200 mediates anti-tumor activity through a novel dual-targeting mode Michael D. Oberst, Dror Luger, Micheal Kebede, Devi Gunasekera, Meital Gadrich, Yonit Ben David, Leah Asulin, Noam Grossman, Reut Fuchs, Hezi Sasson, Yael Diesendruck, Guy Nimrod, Tim Wyant, Ronald Herbst, Yanay Ofran, Inbar Amit
• 439 · PDF Inhibition of extracellular matrix remodeling and metastatic activity by dichloroacetate and chloroquine in the presence of arsenite in 4nqo-induced oral squamous cell carcinoma Mounia Benbelkacem, Nabila Moulai, Eimen Kais Kadri, Lina Stamboul, Henni Chader, Wahiba Ouhaioune, Mehdi Bourouba
• 440 · PDF Targeting oncogenic TBRI signaling inhibits androgen-independent prostate cancer growth and metastasis Per Flodbring Larsson, Alexej Schmidt, Yabing Mu, Guangxiang Zang, Jie Song, Vishnupriya Gajavilli, Junting Tao, Olena Rahkimova, Madelene Ericsson, Karthik Aripaka, Sofia Halin Bergstroem, Wei Yuan, Denisa Bogdan, Aaron Zhang, Jon Welti, Anders Bergh, Johann de Bono, Carl-Henrik Heldin, Marene Landstroem
• 441 · PDF Breaking the KRAS inhibitor induced resistance-wall: Targeting KRAS-SOS1 to disarm hypoxic survival Jooyun Byun, Heesun Moon, Jongmin Hong, Soye Jeon, Jaeyul Choi, Seung Hyun Jung, Yongjae Park, YoungGil Ahn, In Young Choi
• 442 · PDF Crippling cancer's energy and escape: NAMPT and BCL2 as dual targets in T-ALL John Robert Sanchez, Daisy Diaz-Rohena, Valerio Ciaurro, Min Wu, Francis Roushar, Dennise A. De Jesus-Diaz, Gregory Crimmins, Pratibha Sharma, Vinay Puduvalli, Francisco Vega, Palaniraja Thandapani, Deepa Sampath
• 443 · PDF LMTK2: A novel driver of endocrine resistance in ERalpha+ breast cancer Anna Detry, Sofia Marigliano, Jenna Heinen, Adam Bass, Calley Jones, Rajeev Muthyala, Matthew Goetz, John Hawse
• 445 · PDF Evaluation of HERV-K as an unusual cancer therapeutic target Monica Gordon, James H. Torpey, Andy D. Martin, Benjamin R. Miller, Marica Speranza, Kenneth W. Hance
• 446 · PDF Pre-targeting with click chemistry facilitates selective MMAE activation in CEACAM5+ tumors: A first-in-class approach to enhance clinical benefit in targeted therapy Sangeetha Srinivasan, Maša Alečković, George Coricor, Stefanie Wagner, Jesse M. McFarland, Nathan A. Yee, Tri-Hung Nguyen, Michael Zakharian, Travis L. Biechele, Jose M. Mejia Oneto
• 447 · PDF A M2-like tumor-associated macrophage-targeted nanoparticulate TLR7/8 agonist, UI-102, reprograms its phenotypes to induce potent anti-tumor immunity Yasuhiro Nagai, Ayaka Matsumoto, Nami Mizoguchi, Mina Tsukamoto, Junki Tashiro, Tadashi Inoue, Takatoshi Soga, Naozumi Harada
• 448 · PDF Intranodal chemokine therapy targeting the sentinel lymph node in head and neck squamous cell carcinoma Anais Aurelia Zourelidis, Jonathan Gunn, Tomoya Kurokawa, Sayuri Miyauchi, Kelsey Decker, Peter Vo, Pardis Mohammadzadeh, Jason Wu, Ester J. Kwon, Joseph A. Califano
• 449 · PDF Albumin-based DLL3-targeted nano-immunoconjugates of SN38 preserve potency and demonstrate high-affinity DLL3 binding in small cell lung cancer Mohamed Shanshal, Lin Yang, Liyi Geng, Wendy Nevala, Aaron S. Mansfield, Bharath Wootla, Konstantinos Leventakos, Kyle Korshavn, Svetomir N. Markovic
• 450 · PDF JZY-2233: An antigen-targeted CBP/p300 degrader-antibody conjugate for advanced prostate cancer therapy Mi Wang, Jianzhang Yang, Brandon Bordeau, Shicheng Jin, Yu Wang, Shaomeng Wang
• 451 · PDF Investigating SIX1 as a driver and target for a first in-class EMT degrader in head-and-neck squamous cell carcinoma Vic Scharfenberger, Asad Faili, Lucia Zoe Miehe, Ellen Weber, Samaneh Heydarzadeh, Reinhard Buettner, Tristan Lerbs
• 452 · PDF Therapeutic potential of AURKA inhibition in ER+ inflammatory breast cancer Tanu Sharma, Azadeh Nasrazadani, Ma Wencai, Jennifer Chen, Megumi Kai, Bora Lim, Michael Lewis, Lacey Dobrolecki, The MDACC IBC Team, Nikita Kotlov, Oleg Baranov, Disha Malani, Daria Goncharova, Anastasiya Evdokimova, Francesca Paradiso, Michael Hensley, Rachel Layman, Wendy Woodward
• 453 · PDF Small molecule targeting of SERPINB3 as an anticancer strategy in cervical cancer Sarah Yu, Liyun Chen, Eric Liu, Ethan Memming, Clifford Luke, Gary Silverman, Stephanie Markovina
• 454 · PDF Overcoming PD-1 resistance with a first-in-class dual-mode agent that transforms ‘cold' tumors to ‘hot' Tong Zhu, Lixin Li
• 455 · PDF MC001: A novel chemoimmunotherapy antibody drug conjugate for treating folate receptor alpha expressing pancreatic cancer Seah H. Lim, Hailiang Zheng, Peipei Zhong, Tawei Huang
• 456 · PDF Discovery of KAT6A degrader enabled by structural proteomics and AI Yonatan Kedem, Nitzan Simchi, Anjana Shenoy, Andrew Morley, Alon Shtrikman, Michal Ran Shchory, Yaron Ben Shoshan-Galeczki, Dimitri Kovalerchik, Iris Alchanati, Galina Otonin, Noam Cohen, Gali Arad, Eran Seger, Kirill Pevzner
• 457 · PDF Nebivolol triggers apoptosis, ferroptosis and necroptosis in triple-negative breast cancer Wangjia Cao, Anh Vuong, Somik Chattertjee, Tagari Samanta, Radbod Darabi, Ashok Kumar, Benny A. Kaipparettu, Meghana Trivedi
• 1320 · PDF Interim results of clinical trial phase 1 of pan-mKARS or PTEN loss tumor targeting peptide drug conjugates (Maleimide-KGDEVD-Doxorubicin/Exatecan) Byoungmo Kim, Ha Kyeoung Lee, Yun-Gun Ko, Kyu-pyo Kim, Youngro Byun, Sang Yoon Kim
• 5646 · PDF Fully human monoclonal antibodies for antibody drug conjugate development to a cell surface target expressed in cancers with unmet needs Ginette Serrero, Jorge Marquez, Jianping Dong, Jun Hayashi
• 7455 · PDF The therapeutic potential of CCL5 and endoglin in ER-positive breast cancer Dominick Lomonaco, Kideok Jin

在完整检索应用中浏览本分会场 →